Ropes & Gray represented Adaptimmune Therapeutics plc in connection with its entry into a definitive agreement for the sale, including all intellectual property rights, of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million in cash to be paid at closing and up to $30 million in potential future payments upon achievement of certain milestones. The deal was announced in a July 28 press release and is expected to close before the end of the week.
The Ropes & Gray team was led by mergers & acquisitions partner Jackie Cohen, counsel Aileen Kim, and life sciences licensing partner David McIntosh and included tax partners David Saltzman and Andrew Howard.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.